6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome.

about

6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome.

Item

http://www.wikidata.org/entity/Q36858958

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.

@en

type

Item

label

6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.

@en

prefLabel

6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.

@en

P1476

6-weekly bevacizumab versus 4- ...... egeneration: a 2-year outcome.

@en

P2093

Nicholas M Hickley

http://www.w3.org/2001/XMLSchema#string

Patrick J Chiam

http://www.w3.org/2001/XMLSchema#string

Venkat Kotamarthi

http://www.w3.org/2001/XMLSchema#string

Vivian W Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration?

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial).

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration.

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

P304

551-555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18240/IJO.2016.04.12

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27162727

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

4853350

http://www.w3.org/2001/XMLSchema#string